DDO-2728 is a selective pyrazolopyrimidine-based inhibitor of ALKBH5 with an IC50 of 2.97 μM. It increases the levels of N6-methyladenosine (m6A) modifications in acute myeloid leukemia (AML) cells and exhibits antiproliferative activity in these cells. It also demonstrates anti-tumor efficacy in the MV4−11 xenograft model.